Respiratory Inhalers Market to Surge Past US$ 44.8 Billion by 2025 with leading players - Cipla Ltd., AstraZeneca, Merck & Co., Inc., GlaxoSmithKline plc, OMRON Healthcare Europe B.V.

The Global Respiratory Inhalers Market, by Product Type (Dry Powder Inhalers (Single Unit Dose, Multi Dose and Multi Unit Dose), Metered Dose Inhalers and Nebulizers (Compressed, Mesh and Ultrasonic Inhalers), by Application (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension and Cystic Fibrosis), by Technology (Digital and Manual), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 27,424.4 million in 2016 and is projected to exhibit a CAGR of 5.7% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights.

Chronic obstructive pulmonary disease (COPD) is a life-threatening disease affecting the lungs characterized by acute breathlessness. In 2015, it was estimated that around 3 million deaths occurred due to sever Chronic Obstructive Pulmonary Disease (COPD), with 90% fatalities reported in low and middle income countries. The two most common forms of COPD include Chronic Bronchitis and Emphysema. According to American Lung Association (ALA), in 2011, over 24 million people in the U.S. suffered from COPD, including 10 million Chronic Bronchitis and over 4.7 million Emphysema cases. The major reason for chronic obstructive pulmonary disease is exposure to tobacco smoke through active or passive smoking. Most chronic obstructive pulmonary disease cases are preventable by avoiding tobacco smoking. However, countries need to adopt the WHO Framework Convention on Tobacco Control (WHO-FCTC) and follow the MPOWER package of measures so that non-smoking becomes the norm globally.

For In depth Information Get FREE Sample Copy of this Report at: https://www.coherentmarketinsights.com/insight/request-sample/227

Some of the major players involved in global respiratory inhalers market:

1. AstraZeneca
2. Beximco Pharmaceuticals Ltd.
3. Boehringer Ingelheim GmbH
4. Cipla Ltd.
5. GlaxoSmithKline plc
6. Koninklijke Philips N.V.
7. Merck & Co., Inc.
8. OMRON Healthcare Europe B.V.
9. PARI Medical Holding
10. Teva Pharmaceutical Industries Ltd.

Asthma is also one of the prime conditions leading to respiratory, disease which is characterized by recurring attacks of panting and wheezing. The severity and frequency of asthma varies according to individual. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people (1 in 13) in the U.S. were suffering from asthma. Under 18 age group, 6.2 million people suffered from asthma. Each year asthma accounts for 14.2 million physician office visits, and 1.8 million emergency visits.

Increasing incidence of Asthma is a major factor driving growing demand for respiratory inhalers, thus boosting growth of the respiratory inhalers market. For instance, according to Canadian Lung Association (CLA), in 2014, 2.5 million people in Canada suffered from asthma, including 1 million males and 1.4 million females. The number of people suffering from asthma accounted for 0.9 million in Ontario, 0.6 million in Quebec, 0.3 million in British Colombia, and Alberta states of Canada. According to Health and Safety Executive (HSE), a U.K.-based organization, each year, 200 to 300 new cases of occupational asthma, 4,000 COPD deaths, 200 to 300 new cases of Pneumoconiosis, and 20-50 new cases of Silicosis were reported in the U.K. In 2015, it also reported 2,542 mesothelioma and 467 asbestos-related deaths.

Inhalers hold significant importance in the treatment of asthma and chronic obstructive pulmonary disease, as it helps deliver medicines that directly acts on air passage and lungs. This signifies the higher concentrations of drug at target site, with lower systemic exposure thus also have low adverse effects than the oral or intravenous administration of drug. However, inhalers cause suboptimal use and low efficacy. The design of inhalers also plays an important role in drug deposition, the characteristics of the inhaled medicine, and on the ability of the patient to use the device. This in turn, poses as a major factor restraining growth of the respiratory inhalers market.

Browse 32 Market Data Tables and 25 Figures spread through 195 Pages and in-depth TOC on Respiratory Inhalers Market by Product Type (Dry Powder Inhalers (Single Unit Dose, Multi Dose and Multi Unit Dose), Metered Dose Inhalers and Nebulizers (Compressed, Mesh and Ultrasonic Inhalers), by Application (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension and Cystic Fibrosis), by Technology (Digital and Manual), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2025

To know the latest trends and insights prevalent in the Respiratory Inhalers Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/respiratory-inhalers-market-227

Key takeaways of the market:

-The global respiratory inhalers market is expected to expand at a CAGR of 7% during the forecast period (2017–2025) as there exists a huge unrealized market especially in Asia Pacific, Latin America, Middle East and Africa

-Asthma, a therapeutic application segment is expected to hold a dominant position in the market throughout the forecast period, owing to rising prevalence of asthma

-North America is expected to dominate the market, owing to the increasing usage of smart inhalers during the forecast period

-The key players are focusing on combinational therapies, which will drive the market forward

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.